Application of 5G Technology to Conduct Real-Time Teleretinal Laser Photocoagulation for the Treatment of Diabetic Retinopathy
Archivos
Fecha
2021
Autores
Chen, H.
Pan, X.
Yang, J.
Fan, J.
Qin, M.
Sun, H.
Liu, J.
Li, N.
Ting, D. S. W.
Chen, Y.
Profesor Guía
Formato del documento
Articulo
ORCID Autor
Título de la revista
ISSN de la revista
Título del volumen
Editor
JAMA Ophthalmol
Ubicación
https://doi.org/10.1001/jamaophthalmol.2021.2312
ISBN
ISSN
2168-6165 (Print) 2168-6165
item.page.issne
item.page.doiurl
Facultad
Departamento o Escuela
Determinador
Recolector
Especie
Nota general
Resumen
IMPORTANCE: Interest in teleophthalmology has been growing, especially during the COVID-19 pandemic. The advent of fifth-generation (5G) wireless systems has the potential to revolutionize teleophthalmology, but these systems have not previously been leveraged to conduct therapeutic telemedicine in the ophthalmology field. OBJECTIVE: To assess the feasibility of 5G real-time laser photocoagulation as a telemedicine-based treatment for diabetic retinopathy (DR). DESIGN, SETTING, AND PARTICIPANTS: This was a prospective study involving a retinal specialist from the Peking Union Medical College Hospital in Beijing, China, who performed online 5G real-time navigated retinal laser photocoagulation to treat participants with proliferative or severe nonproliferative DR who had been recruited in the Huzhou First People's Hospital in Zhejiang Province, China, located 1200 km from Beijing from October 2019 to July 2020. INTERVENTIONS: These teleretinal DR and laser management procedures were conducted using a teleophthalmology platform that used the videoconference platform for teleconsultation, after which telelaser planning and intervention were conducted with a laser system and a platform for remote computer control, which were connected via 5G networks. MAIN OUTCOMES AND MEASURES: Diabetic eye prognosis and the real-time laser therapy transmission speed were evaluated. RESULTS: A total of 6 participants (9 eyes) were included. Six eyes were treated via panretinal photocoagulation alone, while 1 eye underwent focal/grid photocoagulation and 2 eyes underwent both panretinal photocoagulation and focal/grid photocoagulation. The mean (SD) age was 53.7 (13.6) years (range, 32-67 years). The mean (SD) duration of diabetes was 14.3 (6.4) years (range, 3-20 years). The mean (SD) logMAR at baseline was 0.32 (0.20) (20/30 Snellen equivalent). Retinal telephotocoagulation operations were performed on all eyes without any noticeable delay during treatment. The mean (SD) number of panretinal photocoagulation laser spots per eye in 1 session was 913 (243). CONCLUSIONS AND RELEVANCE: This study introduces a novel teleophthalmology paradigm to treat DR at a distance. Applying novel technologies may continue to ensure that remote patients with DR and other conditions have access to essential health care. Further studies will be needed to compare this approach with the current standard of care to determine whether visual acuity or safety outcomes differ.
Descripción
Lugar de Publicación
Auspiciador
Palabras clave
ADULT AGED, BEIJING DIABETIC RETINOPATHY, DIAGNOSTIC IMAGING, SURGERY FEMALE HUMANS, LIGHT COAGULATION, ADVERSE EFFECTS MALE MIDDLE AGED PROSPECTIVE STUDIES, TELEMEDICINE TREATMENT OUTCOME, WIRELESS TECHNOLOGY